Unlocking the value of innovative medicines: Insights from the advanced therapy medicinal products (ATMP) innovation systems in Germany and Sweden

•Non-technological barriers are the main hindrances for ATMP uptake in Europe.•Sweden has low access to ATMPs, innovative HTA and reimbursement models are needed.•Germany is one of the best countries in terms of ATMP development and diffusion in Europe.•Successful ATMPs development and uptake requires substantial changes in the whole ecosystem.